Six healthy male subjects received equimolar amounts of two 5-hydroxytryptamine (5-HT) precursors, 5-hydroxy-L-tryptophan (5-HTP) and y-L-glutamyl-5-hydroxy-Ltryptophan (glu-5-HTP), on two occasions in a randomised cross-over study. There were marked increases in urinary 5-HTP and 5-HT excretion after infusion of both compounds. Mean urinary excretion rate of 5-HT, which was < 0.7 nmol min-1 before dosing, rose to a peak value of 412 ± 92 nmol min-1 at the end of 5-HTP infusion and 303 ± 29 nmol min-1 after administration of glu-5-HTP. This occurred without significant changes in blood 5-HT levels measured in platelet-rich plasma. These findings provide further evidence that the increase in urine 5-HT after administration of both 5-HT precursors is largely due to 5-HT synthesised within the kidney.
Introduction Methods
The mammalian kidney contains all the major enzymes required for the synthesis and degradation of 5-hydroxytryptamine (5-HT) [1, 2] . Intrarenal synthesis of 5-HT occurs in rats given its immediate precursor, 5-hydroxytryptophan (5-HTP), and it has been suggested that 5-HT may act as a counterregulatory paracrine substance to dopamine in the local regulation of sodium excretion [2] [3] [4] . We previously administered 5-HTP and its glutamyl derivative, y-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP), in healthy men and demonstrated a marked increase in urinary 5-HT excretion after both compounds [5, 6] .
We argued that this large increment in 5-HT excretion cannot be explained by extrarenal production of 5-HT and that it is principally due to intrarenally generated 5-HT. In the present study, we have estimated 5-HTP and 5-HT concentrations in platelet-rich plasma (PRP), in addition to urinary 5-HTP and 5-HT excretion, after infusion of equimolar amounts of both 5-HT precursors to investigate our hypothesis further.
We chose to measure 5-HT in PRP rather than whole blood since processing of whole blood for 5-HT assay inevitably leads to disruption of red blood cells with release of oxyhaemoglobin resulting in oxidation of 5-HT [7] .
Six healthy male volunteers (age range 22-35 years) gave informed written consent to be studied on two separate days, at least 1 week apart, in this randomised cross-over study which was approved by the Lothian Ethics of Medical Research Committee. They abstained from alcohol for 24 h and fasted from 22.00 h the evening before each study day. They attended the clinical investigation unit at 08.00 h after drinking 500 ml of water 1 h previously. The subjects received intravenous 0.9% saline at 5 ml min-' and drank 150 ml of water half-hourly over the next 6 h. They emptied their bladders at 2 h and serial urine collections of 30 min duration were made thereafter. One hour later, an equimolar dose of 5-HTP (10 gg kg-' min-) or glu-5-HTP (16.6 jg kg-l min-') was infused intravenously for 60 min.
Venous blood samples were collected via a 16 G cannula before and every 30 min for 3 h after the start of the infusion. The blood sample (9 ml) was dispensed into an acid-citrate-dextrose anticoagulant (1 ml) consisting of citric acid (8 g l-l), trisodium citrate (22 g F-') and glucose (20 g l-1) [8] . 
Results
The 5-HTP concentrations in PRP and urinary excretion rates of 5-HTP on the two study days are shown in Figure 1 . 5-HTP was undetectable in baseline PRP and urine samples. Cmax for 5-HTP in PRP was 1365 ± 302 nmol 1-F and AUC(0-3 h) was 1763 ± 250 nmol 1-' h after administration of 5-HTP. The corresponding values after glu-5-HTP infusion were lower at 471 ± 95 nmol 1-' (95% CI of the difference: 539 to 1249, P < 0.005) and 934 ± 185 nmol 1-' h (95% CI of the difference: 464 to 1193, P < 0.005). The 3 h cumulative 5-HTP excretion was 2.5 times greater after glu-5-HTP (44.0 ± 8.6 jmol) than after 5-HTP infusion (17.6 ± 2.1 ,umol; 95% CI of the difference: 18.5 to 34.4, P < 0.001). The apparent renal clearance of 5-HTP over the first hour was higher after glu-5-HTP (1357 ± 348 ml min-) than after 5-HTP (246 ± 56 ml min-'; 95% CI of the difference: 734 to 1487, P < 0.001). were not significantly different at 37.4 ± 4.6 gmol and 32.0 ± 4.5 jmol respectively (95% CI of the difference: -0.6 to 11.5). Two subjects complained of nausea, and one of these two vomited, at the end of 5-HTP infusion. There were no ill-effects following glu-5-HTP infusion.
Discussion
The present study confirms our previous observations that both 5-HTP and glu-5-HTP markedly increase urinary 5-HT excretion [5, 6] . In addition, we have now shown that this occurs without concomitant changes in circulating 5-HT levels. These findings support our hypothesis that urine 5-HT, after infusion of both 5-HT precursors, is largely derived from intrarenal synthesis of 5-HT. Although a placebo day was not included in this study, we previously showed that the saline infusion and water loading employed in the protocol do not affect urinary 5-HTP or 5-HT excretion [5, 6, 9] .
The high renal clearance value of 5-HTP observed after administration of glu-5-HTP suggests that urine 5-HTP after glu-5-HTP is also predominantly produced intrarenally. The rise in circulating 5-HTP is probably caused both by its formation within the kidney (followed by recirculation) and extrarenal transformation of glu-5-HTP to 5-HTP since the enzyme y-glutamyl transferase required for the conversion of glu-5-HTP to 5-HTP is widely distributed in the body although its concentration in renal tissue is considerably greater than elsewhere [10] . Gastrointestinal side effects after administration of 5-HTP appear to be related to the plasma 5-HTP concentrations [11, 12] . In the present study, two subjects developed nausea at the end of 5-HTP infusion at the time when peak circulating levels occurred. In contrast, peak circulating 5-HTP levels were much lower after infusion of the glutamyl compound and no adverse effects were observed. 5-HTP is decarboxylated to 5-HT by aromatic L-amino acid decarboxylase. This enzyme has a ubiquitous distribution with high activity in the kidney and liver [13] . The absence of an increase in circulating 5-HT, particularly after administration of 5-HTP, suggests that 5-HT, if produced extrarenally, is rapidly metabolised and cleared from the circulation.
This study therefore provides further evidence that 5-HT is synthesised intrarenally after administration of both 5-HTP and glu-5-HTP in man. Definitive proof of this will require estimations of 5-HTP and 5-HT in the renal artery and vein, in addition to urinary measurements. The glutamyl compound exhibits greater renal selectivity and is better tolerated [6] . It could be used as a valuable pharmacological research compound for the investigation of the renal formation and effects of 5-HT in man.
